Webinar
Financing biotech companies in a post-COVID
It is undeniable that the COVID-19 crisis has impacted many industries throughout the world, not least the biotech sector.
Join Euronext’s second Biotech Leaders Conference to hear from our panel of experts on the pandemic’s impact on both private and public biotech financing as well as the M&A market. Euronext will also present the findings from our Biotech Barometer H1 2020 and biotech investors survey.
Watch the webinar brought to you by Euronext, KBC Securities, BioWin and Flanders.Bio by clicking the ‘START NOW’ button.
Our media partner for this webinar: Labiotech.eu
Topics covered in the webinar
The financing journey of Belgian biotech, argenx
Results from Euronext's Biotech Barometer H1 2020
Presentation of biotech investor survey

Benoit van den Hove
Head of Listing at Euronext Brussels

Eric Castaldi
Chief Financial Officer at argenx

Nicolas Meunier
Head of Advisory and IR Solutions at Euronext Corporate Solutions

Fabienne Van den Keere
Senior Advisor, Life Sciences at Korys

Cédric Moreau
Partner at Sofinnova Partners

Bertrand Grimmonpré
Chief Financial Officer at Miracor Medical

Nathalie Van den Haute
Executive Director Corporate Finance at KBC Securities
Post Listing Advisory
Post-Listing Advisory supports newly listed and mature companies with strategic IR planning, market intelligence and investor targeting services to build long-term capital markets success.
- Equity story refinement and IR action plans
- Shareholder and analyst perception studies
- Ongoing support across the IR calendar
